In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer to buy Sanofi's Campto if Aventis buyout happens

Executive Summary

Contingent upon the successful takeover of Aventis by Sanofi-Synthelabo, Pfizer will acquire worldwide exclusive rights (outside of Japan) to Sanofi's (now Aventis's) colorectal cancer drug Campto (irinotecan) for €510mm ($620mm).
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase
    • R&D and Marketing (Licensing)

Related Companies